Pim-3, a proto-oncogene with serine/threonine kinase activity, was enhanced in hepatocellular carcinoma (HCC) tissues. To address the roles of Pim-3 in HCC development, we prepared transgenic mice that express human Pim-3 selectively in liver. The mice were born at a Mendelian ratio, were fertile and did not exhibit any apparent pathological changes in the liver until 1 year after birth. Pim-3-transgenic mouse-derived hepatocytes exhibited accelerated cell cycle progression. The administration of a potent hepatocarcinogen, diethylnitrosamine (DEN), induced accelerated proliferation of liver cells in Pim-3 transgenic mice in the early phase, compared with that observed for wild-type mice. Treatment with DEN induced lipid droplet accumulation with increased proliferating cell numbers 6 months after the treatment. Eventually, wild-type mice developed HCC with a frequency of 40% until 10 month after the treatment. Lipid accumulation was accelerated in Pim-3 transgenic mice with higher proliferating cell numbers, compared with that observed for wild-type mice. Pim-3 transgenic mice developed HCC with a higher incidence (80%) and a heavier burden, together with enhanced intratumoral CD31-positive vascular areas, compared with that observed for wild-type mice. These observations indicate that Pim-3 alone cannot cause, but can accelerate HCC development when induced by a hepatocarcinogen, such as DEN.
Introduction
There were over 667 000 new cases of hepatocellular carcinoma (HCC) worldwide in 2005. The 5-year survival rate of individuals with hepatic malignancy is only 8.9% despite aggressive conventional therapy, making hepatic malignancy the second most lethal cancer among human malignancies (Farazi and DePinho, 2006; Umemura et al., 2009) . Hepatocellular carcinoma usually arises in conditions that can cause liver cirrhosis, such as chronic hepatitis B and C viral infection, chronic alcohol consumption and intake of food contaminated with aflatoxin-B 1 . These conditions generally provoke continuous rounds of hepatocyte damage in the setting of chronic hepatitis or liver cirrhosis, and eventually activate resident or inflammatory non-parenchymal cells to produce growth factors and cytokines (Otani et al., 2005) . The produced factors can drive compensatory and aberrant proliferation of surviving hepatocytes and development of pre-malignant dysplastic nodules that form the nucleus of neoplastic lesions. Only recently has the molecular analysis of human HCC unraveled many genetic and epigenetic alterations that result in the deregulation of key proto-oncogenes and tumor-suppressor genes, including TP53, b-catenin, ErbB receptors family members, met and its ligand, hepatocyte growth factor, p16, E-cadherin and cyclo-oxygenase 2 (Hosono et al., 1993) . However, roles of other proto-oncogenes and tumor suppressor genes in HCC development still remain elusive (Thorgeirsson and Grisham, 2002) .
We previously identified Pim-3, a proto-oncogene with serine/threonine kinase activity, as the gene selectively expressed in pre-malignant and malignant lesions of the mouse HCC model in transgenic mice expressing hepatitis B virus surface antigen (Fujii et al., 2005) . Pim-3 was originally identified as a depolarization-induced gene, KID-1, in PC12 cells, a rat pheochromocytoma cell line (Feldman et al., 1998) . Subsequently, Deneen et al. (2003) demonstrated that Pim-3 gene transcription was enhanced in the EWS/ETS-induced malignant transformation of NIH 3T3 cells, suggesting the involvement of Pim-3 in tumorigenesis. Consistently, we observed that Pim-3 expression was enhanced in carcinomas but not in normal tissues of human endoderm-derived organs, including the liver (Fujii et al., 2005) , pancreas (Li et al., 2006) , colon (Popivanova et al., 2007) and stomach (Zheng et al., 2008) . Moreover, Pim-3 can inactivate a pro-apoptotic molecule, Bad, and maintain the expression of an anti-apoptotic molecule, Bcl-X L , and prevent apoptosis of human pancreatic cancer and colon cancer cells (Li et al., 2006) . Similarly, the ablation of endogenous Pim-3 by short interfering RNA reduced the cell growth of human HCC cell lines by inducing their apoptosis (Fujii et al., 2005) .
These observations prompted us to investigate the effects of liver-specific Pim-3 overexpression on HCC development. Although we could not observe spontaneous HCC development in liver-specific Pim-3 transgenic mice, these mice developed HCC with a higher incidence and a heavier hepatocarcinoma burden, when a potent hepatocarcinogen, diethylnitrosamine (DEN), was administered during the suckling period. These results suggest that Pim-3 can accelerate but is not likely the primary inducer of HCC development.
Results
Characterization of transgenic mice overexpressing Pim-3 under the control of the albumin promoter Pim-3 transgenic mice were born at a Mendelian ratio, were fertile and did not show any apparent abnormalities in the liver until 1 year after birth (data not shown). We first examined the expression pattern of Pim-3 in Pim-3 transgenic mice. Mouse Pim-3 messenger RNA (mRNA) was detected in liver at a similar extent in both wild-type (WT) and Pim-3 transgenic mice, whereas human Pim-3 mRNA was exclusively detected in Pim-3 transgenic mice (Figure 1b) . Consistently, Pim-3 protein was detected abundantly in liver of Pim-3 transgenic mice but not WT mice (Figure 1b ). Pim-3 protein was also detected in the heart and kidney of Pim-3 transgenic mice, but not of WT mice ( Figure 1c) . As anti-Pim-3 recognizes both human and mouse Pim-3 to a similar degree, we further examined the mRNA of human and mouse Pim-3 in the liver, heart and kidney. Human Pim-3 mRNA was detected in the liver of Pim-3 transgenic mice, but not in other organs (Figure 1d ). These observations would indicate that Pim-3 transgenic mice express human Pim-3 abundantly and selectively in liver.
Enhanced hepatocyte proliferation by Pim-3 overexpression As Pim-3 can phosphorylate a pro-apoptotic molecule, Bad, at the Ser 112 residue but not at the Ser 136 residue, we first examined the phosphorylation states of Bad, to prove the functionality of the Pim-3 gene, selectively overexpressed in liver. Bad was constitutively phosphorylated at Ser 112 in hepatocytes from Pim-3 transgenic but not WT mice (Figure 2a) . However, the level of phospho-Ser
136
-Bad was not enhanced in Pim-3 transgenic mice. These observations would indicate that overexpressed Pim-3 was functional in terms of its capacity to phosphorylate Bad, its substrate. The levels of cyclin D1 and proliferating cell nuclear antigen (PCNA) in hepatocytes were increased in Pim-3 transgenic mice, compared with that observed for WT mice (Figure 2b ). Moreover, cell cycle analysis of isolated heptocytes revealed that the proportion of the cells in subG1 phase, which represent apoptotic cells, was marginally but not significantly decreased in Pim-3 transgenic mice. However, the proportion of the cells in G2/M phase was significantly increased in Pim-3 transgenic mice compared with that observed for WT mice (Figure 2c ). To exclude the possibility that Hepatocellular carcinoma in Pim-3 transgenic mice Y Wu et al isolation of hepatocytes from liver gave rise to artificially high proportion of cells in G2/M phase, we also enumerated the proportion of cells in G2/M phase by immunostaining liver tissues with anti-cyclin B1 antibodies. The proportion of cyclin B1-positive cells were significantly higher in Pim-3 transgenic mice than in WT mice (Figure 2d ). Moreover, TUNEL (terminal transferase dUTP nick end labeling) staining failed to detect any significant differences in the numbers of apoptotic hepatocytes between untreated WT and Pim-3 transgenic mice (Figure 2e ). These observations suggest that Pim-3 overexpressed in liver can accelerate the cell cycle progression of hepatocytes.
Enhanced liver damage in Pim-3 transgenic mice We then treated Pim-3 transgenic and WT mice with DEN, a potent hepatocarcinogen. Both Pim-3 transgenic and WT mice survived exposure to DEN. Serum alanine amino transferase levels, a marker of liver injury, increased with maximal levels less than 1 000 IU/ l, and were significantly but not markedly higher in Pim-3 transgenic mice than in WT mice (Figure 3a ). These observations suggest that DEN-induced acute liver injury was mild. This may account for comparable levels of apoptosis in liver after DEN treatment until 72 h after the injection (Figures 3b and c) . In contrast, PNCA and cyclin D1 levels were higher, at 72 h after the injection in Pim-3 transgenic mice, than those observed for WT mice (Figures 3d and e) . Moreover, proliferating cells were progressively increased in the centrilobular region of Pim-3 transgenic mice and to a lesser degree in WT mice (Figures 3f and g ). The crucial involvement of tumor necrosis factor (TNF)-a in hepatocyte proliferation (Yamada et al., 1997) prompted us to determine intrahepatic expression of TNF-a mRNA levels. The TNF-a mRNA levels were increased significantly at 48 h after DEN treatment (Figure 3h ). These observations Figure 2 The effects of Pim-3 overexpression on hepatocyte functions. Hepatocytes were obtained from 3-week-old wild-type (WT) and Pim-3 transgenic (Tg) mice and used for the following analyses. (a and b) Protein was extracted from purified hepatocytes from WT and Tg mice, and was subjected to immunoblotting using anti-phospho-Ser 112 -Bad, anti-phospho-Ser
-Bad, anti-Bad, anti-cyclin D1 and anti-PCNA (proliferating cell nuclear antigen) antibodies as described in Materials and methods section. Representative results from four independent experiments are shown in (a). The intensity of each band was determined using National Institutes of Health (NIH) Image Analysis software version 1.62 (NIH, Bethesda, MD, USA), and its ratios to b-actin were calculated and are shown in (b) (n ¼ 4). Open boxes, WT mice; closed boxes, Pim-3 Tg mice. **Po0.01. (c) DNA contents were determined for hepatocytes from WT and Pim-3 Tg mice as described in Materials and methods section. Representative results from five independent experiments are shown here. After the proportion of each fraction was determined, mean and 1 s.d. were calculated and are shown in the Table ( indicate that the DEN challenge enhanced liver damage in Pim-3 transgenic mice, compared with that observed for WT mice, despite increased hepatocyte proliferation.
Enhanced hepatocarcinogenesis in Pim-3 transgenic mice
We next examined the changes in liver in the later phase of DEN treatment. As lipid droplet accumulation precedes the onset of DEN-induced HCC development (Wang et al., 2009) , we examined the lipid droplet accumulation in liver after DEN treatment. Lipid droplet accumulation was more evident in Pim-3 transgenic mice than in WT mice, until 6 months after DEN treatment (Figure 4a ). The PCNA-positive proliferating cell numbers were progressively increased in Pim-3 transgenic mice and to a lesser degree in WT mice (Figures 4b and c) . Tumor necrosis factor-a was potentially involved in hepatocarcinogenesis (Roberts and Kimber, 1999; Schwabe and Brenner, 2006) . Moreover, its expression was enhanced to a greater extent in Pim-3 transgenic mice than that observed for WT mice promptly after treatment with a high-dose of DEN ( Figure 3h ). Hence, we investigated TNF-a mRNA expression in the course of hepatocarcinogenesis together with other pro-inflammatory cytokines, such as interleukin-1. Indeed, TNF-a mRNA expression was enhanced in Pim-3 transgenic and WT mice after DEN treatment, but the increase was more evident in Pim-3 transgenic mice ( Figure 4f ). A similar tendency was observed for interleukin-1b but not for interleukin-1a (Figures 4d and e). Dysplastic cells were observed and lobules were distorted in livers of Pim-3 transgenic mice, but not of WT mice, 6 months after DEN treatment ( Figure 5a ). At 10 months after the injection, nodules consisting of highly dysplastic malignant cells were observed in liver of Pim-3 transgenic mice and to a lesser extent in WT mice (Figure 5a ). Macroscopically, approximately half of male WT mice developed HCC nodules at 10 months after DEN injection , consistent with the previous report (Yang et al., 2006) . In contrast, most Pim-3 transgenic mice developed HCC nodules by 10 months after DEN treatment, with higher relative liver weight and larger numbers of HCC nodules than WT mice (Figures 5b-e) .
The enhanced hepatocarcinogenesis in Pim-3 transgenic mice may mirror the fact that neovascularization, an essential process for hepatocarcinogenesis, was augmented in Pim-3 transgenic mice compared with that observed for WT mice, as demonstrated by increases in CD31-positive areas in the liver (Figures 5f and g ).
Discussion
We previously observed that Pim-3 was expressed selectively in pre-malignant and malignant lesions of the mouse HCC model in transgenic mice expressing hepatitis B virus surface antigen (Fujii et al., 2005) . Moreover, Pim-3 protein was detected in a substantial proportion of HCC cells and precancerous lesions in human liver samples, but not normal human liver. Furthermore, Pim-3 protein was also detected in regenerating bile ductules that are assumed to be the proliferation of hepatic stem cells after chronic injury. These observations suggested potential roles of aberrantly expressed Pim-3 in hepatocarcinogenesis. To Hepatocellular carcinoma in Pim-3 transgenic mice Y Wu et al address the roles of Pim-3, we generated transgenic mice that constitutively express human Pim-3 selectively in liver. Untreated hepatocytes derived from these transgenic mice exhibited enhanced cell proliferation compared with those obtained from WT mice. However, these transgenic mice did not develop HCC spontaneously. Hence, enhanced cell proliferation cannot per se result in carcinogenesis in liver. Kinase activation generally requires a posttranslational modification, particularly, phosphorylation in its regulatory domain. However, another member of the Pim kinase family, Pim-1, is constitutively active without any further alteration in its conformation because it lacks any regulatory domain . Similarly, Pim-3 lacks any regulatory domain (Fujii et al., 2005) and Pim-3 complementary DNA (cDNA) alone induced phosphorylation of its target protein, Bad, at Ser 112 when it was transfected into human pancreatic cancer cell lines (Li et al., 2006) . Consistently, Pim-3 transgenic mice exhibited enhanced phosphorylation of Bad at Ser 112 in the liver. The proapoptotic activity of Bad is regulated by its phosphorylation at (She et al., 2005) . Unphosphorylated Bad binds and eventually inactivates anti-apoptotic family members, primarily Bcl-X L and even Bcl-2 (Yang et al., 1995; Zha et al., 1996) . As phosphorylation of Bad at Ser 112 or Ser 136 can result in the liberation of Bcl-X L and Bcl-2, which can prevent apoptosis (Chen et al., 2005) , phosphorylated Bad represents its inactive form. However, both WT and Pim-3 transgenic mice developed apoptosis in liver to a similar extent when they were treated with a potent hepatocarcinogen, DEN. These observations suggest that phosphorylated Bad is not sufficient to prevent apoptosis induced by potent hepato-cytotoxic drugs such as DEN.
Pim-3 transgenic mice developed HCC with a higher incidence and a heavier burden than WT mice when both were treated similarly with DEN. Hepatocytes, particularly those in the centrilobular region, metabolized DEN into an alkylating agent that, in turn, can induce DNA damage and mutations in hepatocytes (Verna et al., 1996) . Simultaneously, DEN metabolites can generate reactive oxygen species (ROS) Schwabe and Brenner, 2006) . When treated with DEN, mice with liver-specific deletion of an essential kinase for NF-kB activation, IKKb, generated increased levels of ROS in hepatocytes, together with enhanced hepatocyte death and augmented compensatory hepatocyte proliferation. The net result was exaggerated HCC development with a high cell proliferation rate as evidenced by increased PCNA-and cyclin D1-positive cell numbers in liver . Similarly, DEN treatment augmented hepatocyte proliferation but not apoptosis in Pim-3 transgenic mice compared with that observed in WT mice, as evidenced by increased PCNA-and cyclin D1-positive cell numbers in liver. These data may account for accelerated hepatocarcinogenesis in Pim-3 transgenic mice. However, several lines of evidence indicate the potential involvement of other Pim kinases, Pim-1 and Pim-2, in NF-kB activation (Hammerman et al., 2004; Zemskova et al., 2008) . Thus, it still remains to be investigated whether the Pim-3 transgene can induce ROS generation in a similar manner as the IKKb deletion.
Liver injury causes liver regeneration primarily through hepatocyte division but if hepatocyte division is impaired, liver repair requires the recruitment of hepatic oval cells (Ma et al., 2006) . Oval cells mainly express a-fetoprotein but not albumin, and can proliferate and differentiate into both hepatocytes and bile duct cells. Several independent groups claimed that HCC cells can arise from oval cells (Braun et al., 1989) . Mice deficient in the IKKb gene in liver developed HCC with an incidence higher than WT mice . In this mouse, the IKKb gene was deleted by using cre recombinase expressed under the control of an albumin promoter/enhancer and therefore, the gene was deleted selectively in albumin-expressing hepatocytes but not in oval cells. As we used the same promoter/ enhancer to prepare transgenic mice, it is likely that the Pim-3 transgene was expressed selectively in hepatocytes but not in oval cells. Thus, the Pim-3 transgene mainly acted on hepatocytes to promote carcinogenesis, although its effects on oval cell proliferation cannot completely be excluded.
Accumulating evidence indicates that Pim-1, a member of the Pim kinase family, can progress cell cycle by phosphorylating several cell cycle regulators and altering their activities. Pim-1 can phosphorylate the phosphatase, Cdc25A, thereby increasing its phosphatase activity (Mochizuki et al., 1999) . Moreover, Pim-1 can phosphorylate G1-specific inhibitor p21 (Waf), a cyclin-dependent kinase inhibitor, and induce its cytoplasmic localization (Wang et al., 2002) . Furthermore, Pim-1 can phosphorylate the kinase Cdc25C-associated kinase (C-TAK)-1 and decrease its kinase activity (Bachmann et al., 2004) , whereas Pim-1 can phosphorylate and activate the G2/M-specific phosphatase Cdc25C. Alteration of the activities of these molecules can result in cell cycle progression, particularly during the G2/M phase. Pim-3 and Pim-1, but not Pim-2, bind to a consensus peptide substrate (AKRRRHPSGPPTA) with a strikingly high affinity, having K d value in the range of 40-60 nM (Bullock et al., 2005) . Thus, it is likely that Pim-3 can phosphorylate these cell cycle regulators similarly as Pim-1. Supporting this idea, recombinant Pim-3 protein can phosphorylate p21/Waf in vitro (Morishita et al., 2008) . This may account for the observations that cell cycle progression was accelerated in Pim-3 transgenic mouse-derived hepatocytes compared with WT mice, as evidenced by increased proportion of the cells in G2/M phase and reciprocally decreased proportion of the cells in G0/G1 phase.
The hepatocarcinogen, DEN, induced TNF-a production consistently with the previous report (Sakurai et al., 2006) and the production was further augmented by Pim-3 overexpression in liver. The crucial involvement of TNF-a in hepatocyte proliferation was proposed by the observation that liver regeneration after partial hepatectomy was impaired in mice deficient in TNF receptor gene (Yamada et al., 1997) . Moreover, accumulating evidence indicates the potential contribution of TNF-a to hepatocarcinogenesis (Roberts and Kimber, 1999; Schwabe and Brenner, 2006) . Furthermore, TNF-a can promote angiogenesis, an essential process for tumorigenesis, by inducing the production of angiogenic factors, such as vascular endothelial growth factor and hepatocyte growth factor (Tamura et al., 1993; Yoshida et al., 1997) . The production of TNF-a was regulated at several steps and the first one was at the transcription level, governed by transcription factors, such as NF-kB and Activator protein-1AP-1 (Manna et al., 2000; Udalova and Kwiatkowski, 2001; Chung et al., 2007) . As Pim-1 can enhance NF-kB transcriptional activity (Zemskova et al., 2008) , Pim-3 might be able to similarly activate NF-kB, thereby inducing TNFa expression.
It is most likely that our transgenic mice expressed a high level of the Pim-3 transgene selectively in hepatocytes. A strong similarity of Pim-3 with another Pim kinase, Pim-1, suggests that Pim-3 can phosphorylate several cell cycle regulators and accelerate cell cycle progression as Pim-1 does. In support of this idea, we observed enhanced cell cycle progression in untreated Pim-3 transgenic mouse-derived hepatocytes compared with that observed for WT mice. However, as evidenced by the absence of spontaneous HCC development in Pim-3 transgenic mice, accelerated hepatocyte proliferation alone cannot induce HCC. The hepatocarcinogen, DEN, can generate O 6 -methlguanine and can frequently induce G-C-to-A-T transition mutations in hepatocytes (Nakatsuru et al., 1993) . The Pim-3 transgene can enhance the proliferation of hepatocytes through G-Cto-A-T transition mutations, thereby accelerating HCC development. We previously observed that Pim-3 expression was detected in pre-malignant and malignant lesions but not in normal tissues of liver in humans and mice (Fujii et al., 2005) . Thus, Pim-3 may be a promoter but not an initiator of HCC development, and blocking of Pim-3 activity can delay and/or prevent HCC development.
Materials and methods

Preparation of Pim-3 transgenic mice
The mouse albumin enhancer/promoter region ( Figure 1a ) was a kind gift from Dr Palmiter (University of Washington, Seattle, WA, USA; Pinkert et al., 1987) . Full-length human Pim-3 cDNA was subcloned 3 to this albumin enhancer/ promoter gene. After being linearized by digestion with NotI, the gene was introduced into fertilized oocytes of C57BL/6 mice using a standard transgenic technique. Genomic DNA was isolated from the tail of the founder and offspring using Nucleospin tissue kit (Macherey Nagel, Du¨ren, Germany) and genotyping was performed by PCR using a specific pair of primers, including a sense primer (5 0 -TTGAACTCATCGACC TGCAGGCAT-3 0 ) flanking the upstream albumin promoter and an antisense primer (5 0 -GCCTTCTCGAAGCTCTCCTT GTCC-3 0 ) inside the human Pim-3 cDNA. Transgenic founder animals were mated with C57BL/6 mice (Charles River Japan, Yokohama, Japan). The male offspring with a heterozygous transgene were used as a transgenic group, whereas those without a transgene were used as a littermate control. All mice were kept under the specific pathogen-free conditions, and all animal experiments in this study complied with the Guidelines of the Care and Use of Laboratory Animals of Kanazawa University.
Hepatocyte isolation
Mouse hepatocytes were isolated by using a two-step perfusion method with some modifications. Briefly, under anesthetization with Avertin (2,2,2-tribromoethanol; Sigma-Aldrich, St Louis, MO, USA), a needle was inserted along the inferior vena cava and the liver was perfused sequentially with phosphate-buffered saline and collagenase-containing buffer at a rate of 5-10 ml/min. The liver was then dissected, suspended in ice-cold phosphate-buffered saline and filtered through a cell strainer with a pore size of 100 mm to remove connective tissue debris and cell clumps. After the cell suspensions were left on ice for 15 min, the resultant precipitates were collected, suspended in DMEM medium (Sigma-Aldrich) and centrifuged at 800 r.p.m. for 2 min. Cell suspensions were further centrifuged in 45% Percoll solution (Sigma-Aldrich) at 1000 r.p.m. for 10 min. The obtained cells were confirmed to consist of more than 95% hepatocytes on the basis of morphological criteria, with a viability of higher than 90% on trypan blue exclusion test. Purified hepatocytes were used for the following DNA content analysis and immunoblotting analysis.
Cell cycle analysis
The obtained hepatocytes were fixed with 70% ethanol at À20 1C. The fixed cells were incubated with 50 mg/ml propidium iodine (Molecular Probes, Eugene, OR, USA) and 1 mg/ ml RNase A for 30 min at room temperature. The DNA content was then analyzed on a FACS Calibur system (BD Biosciences, Bedford, MA, USA). The distribution of cells in each cell-cycle phase was determined by cell ModFit LT software (BD Biosciences).
Protein extraction and western blotting
Hepatocytes or liver tissues were obtained and homogenized with RIPA buffer (Santa Cruz Biotechnology, Santa Cruz, CA, USA) containing proteinase inhibitor cocktail (Roche Diagnostics AG, Rotkreutz, Switzerland). After sonication for 1 min, homogenates were centrifuged at 15 000 g for 15 min at 4 1C to obtain the supernatants. After total protein concentrations were measured using a BCA kit (Pierce Biotechnology, Rockford, IL, USA), resultant supernatants were subjected to immunoblotting using anti-phospho-Ser 112 -Bad, anti-phosphoSer 136 -Bad, anti-Bad, anti-Pim-3, anti-b actin (Sigma-Aldrich); anti-cyclin D1 (Cell Signaling Technology, Beverly, MA, USA) and anti-PCNA antibodies (BD Biosciences) as previously described (Li et al., 2006) .
Chemical-induced liver injury and subsequent hepatocarcinogenesis Three-week old weaning mice were given a single intraperitoneal injection of DEN (Sigma-Aldrich), dissolved in physiological saline solution at a dose 10 mg/kg body weight as previously described (Yang et al., 2006) , to induce hepatocarcinogenesis. To induce acute liver injury, mice were given a dose of 100 mg/kg body weight. Serum alanine amino transferase levels were determined using a Fuji DRICHEM 55500V (Fuji Medical System, Tokyo, Japan) according to the manufacturer's instructions. Mice were killed at the indicated time intervals after the injection to conduct histopathological analysis.
RNA isolation and RT-PCR
Total RNAs were extracted from the organs using RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions and were further treated with RNase-free DNase (Promega, Madison, WI, USA) to deplete residual contaminated DNA. A total of 2 mg RNA was reversetranscribed at 42 1C for 1 h in 20-ml reaction mixture containing Moloney murine leukemia virus reverse trancriptase (Toyobo, Osaka, Japan) and hexanucleotide random primer (Qiagen) to obtain cDNA as previously described (Wu et al., 2008) . Serially twofold diluted cDNA products were amplified for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using a specific set of primers (Table 1 ) using 25 cycles consisting of following reaction conditions: 94 1C for 30 s, 58 1C for 30 s and 72 1C for 1 min in a 25-ml of reaction mixture containing Taq polymerase (Takara Bio, Kyoto, Japan) to evaluate the quantity of the transcribed cDNA. Equal quantities of cDNA products were then amplified for the indicated genes using the specific sets of primers (Table 1) with 35 cycles consisting of following conditions: 94 1C for 30 s, 58 1C for 1 min and 72 1C for 1 min. The resultant PCR products were fractionated on 1.5% agarose gel and visualized by ethidium bromide staining under ultraviolet light trans-illumination. The band intensities were measured using National Institutes of Health Image analysis software, version 1.62, and the ratios to GAPDH were calculated on the assumption that the ratios of untreated animals were set at 1.0.
Histopathological analysis
The liver tissue was fixed in 10% formalin buffered with phosphate-buffered saline (pH 7.2). and embedded in paraffin. Five-mm thick sections were stained with hematoxylin and eosin solution or subjected to the terminal transferase dUTP nick end labeling assay (MBL, Nagoya, Japan) according to the manufacturer's instructions. Immunohistochemical analysis was performed using anti-PNCA (BD Biosciences) or anticleaved caspase-3 antibodies (Cell Signaling Technology). A portion of the liver tissue was snap-frozen, dried at room temperature until the tissues firmly adhered to the slides, and was fixed in cold acetone for 10 min. The sections were blocked with serum-free Protein Block (Dako Cytomation, Glostrup, Denmark) and were incubated with rabbit anti-cyclin B1 antibodies (Santa Cruz Biotechnology). They were further incubated with Alexa Fluor 488-labeled donkey anti-rabbit IgG followed by counterstaining with 4-6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA) in dark. Immunoflurescence was visualized on a Laser Microscope 510 (Carl Zeiss, Hamburg, Germany) and cyclin B1-positive cell proportion was determined on 10 randomly chosen fields at Â 200 magnification. Another slides were used for staining with oil red (Sigma-Aldrich) and hematoxylin counterstaining, or immunohistochemical analysis using anti-CD31 antibodies (BD Pharmingen). The immune complexes were visualized by Envision þ System (Dako Cytomation), a catalyzed signal amplification system or the Elite ABC kit and DAB substrate kit (Vector Laboratories) according to the manufacturer's instructions. The positive cell numbers were enumerated on 10 randomly chosen visual fields at Â 400 magnification. The CD31-postive areas were determined as previously described (Wu et al., 2008) . In brief, CD31-positive areas in the tumor tissue were defined as the intratumoral vascular areas. Areas of active neovascularization (hot spot) were found inside tumor foci by scanning the section at lower magnification and the pixel numbers of CD31-positive areas were then determined on five randomly chosen fields in hot spots of each animal at Â 400 magnification with the help of Photoshop version 7.0. The density of neovascularization was expressed as a percentage of the whole tumor area. All histopathological examinations were conducted by an examiner without any prior knowledge of the experimental procedures. All histopathological examinations were conducted blind, by an examiner without any prior knowledge of the experimental procedures.
Statistical analysis
All obtained data were calculated and expressed as mean ± s.d. The differences were analyzed statistically using one-way analysis of variance, followed by the Turkey-Kramer test. Po0.05 was considered statistically significant. Abbreviations: GADPH, glyceraldehydes-3-phosphate dehydrogenase; IL, interleukin; TNF, tumor necrosis factor.
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